Mendelian randomization study of serum uric acid levels and urate-lowering drugs on pulmonary arterial hypertension outcomes
Abstract This study aims to explore the causal relationships between serum uric acid level and pulmonary arterial hypertension (PAH) using the Mendelian randomization (MR) approach, and to assess the therapeutic impacts of urate-lowering drugs on PAH. Utilizing published genome-wide association stud...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-88887-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823862490427031552 |
|---|---|
| author | Xiaoling Yao Xin Cai Shaoqin Zhang Yuzheng Yang Xiangyan Yang Wukai Ma Zong Jiang |
| author_facet | Xiaoling Yao Xin Cai Shaoqin Zhang Yuzheng Yang Xiangyan Yang Wukai Ma Zong Jiang |
| author_sort | Xiaoling Yao |
| collection | DOAJ |
| description | Abstract This study aims to explore the causal relationships between serum uric acid level and pulmonary arterial hypertension (PAH) using the Mendelian randomization (MR) approach, and to assess the therapeutic impacts of urate-lowering drugs on PAH. Utilizing published genome-wide association study (GWAS) data, we applied MR and colocalization analysis to assess the link between serum uric acid levesl and PAH across four GWAS datasets from two distinct European populations. The validity and reliability of these findings were confirmed through multiple statistical methods, along with an MR analysis of urate-lowering drug targets to investigate their potential effects on PAH treatment. MR analysis revealed a significant positive correlation between serum uric acid levels and PAH (odds ratio (OR) 1.106, 95% confidence intervals (CI) 1.021-1.200, P = 0.014), corroborated by a replication MR analysis (OR 1.859, 95% CI 1.130–3.057, P = 0.015). No significant heterogeneity or horizontal pleiotropy was found in the sensitivity analyses. However, urate-lowering drugs did not demonstrate a significant direct therapeutic effect on PAH. This study establishes a genetic basis for a causal link between serum uric acid levels and PAH. However, urate-lowering drugs do not appear to have a direct causal effect on improving PAH. These findings provide a novel reference point for developing future therapeutic strategies for PAH. |
| format | Article |
| id | doaj-art-7ebf92be3ac8435ba84a71635f9ac645 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-7ebf92be3ac8435ba84a71635f9ac6452025-02-09T12:30:53ZengNature PortfolioScientific Reports2045-23222025-02-0115111010.1038/s41598-025-88887-4Mendelian randomization study of serum uric acid levels and urate-lowering drugs on pulmonary arterial hypertension outcomesXiaoling Yao0Xin Cai1Shaoqin Zhang2Yuzheng Yang3Xiangyan Yang4Wukai Ma5Zong Jiang6Second Clinical Medical College, Guizhou University of Traditional Chinese MedicineDepartment of Rheumatology and Immunology, The First People’s Hospital of GuiyangDepartment of Rheumatology and Immunology, The First People’s Hospital of GuiyangSecond Clinical Medical College, Guizhou University of Traditional Chinese MedicineDepartment of Rheumatology and Immunology, The First People’s Hospital of GuiyangSecond Clinical Medical College, Guizhou University of Traditional Chinese MedicineSecond Clinical Medical College, Guizhou University of Traditional Chinese MedicineAbstract This study aims to explore the causal relationships between serum uric acid level and pulmonary arterial hypertension (PAH) using the Mendelian randomization (MR) approach, and to assess the therapeutic impacts of urate-lowering drugs on PAH. Utilizing published genome-wide association study (GWAS) data, we applied MR and colocalization analysis to assess the link between serum uric acid levesl and PAH across four GWAS datasets from two distinct European populations. The validity and reliability of these findings were confirmed through multiple statistical methods, along with an MR analysis of urate-lowering drug targets to investigate their potential effects on PAH treatment. MR analysis revealed a significant positive correlation between serum uric acid levels and PAH (odds ratio (OR) 1.106, 95% confidence intervals (CI) 1.021-1.200, P = 0.014), corroborated by a replication MR analysis (OR 1.859, 95% CI 1.130–3.057, P = 0.015). No significant heterogeneity or horizontal pleiotropy was found in the sensitivity analyses. However, urate-lowering drugs did not demonstrate a significant direct therapeutic effect on PAH. This study establishes a genetic basis for a causal link between serum uric acid levels and PAH. However, urate-lowering drugs do not appear to have a direct causal effect on improving PAH. These findings provide a novel reference point for developing future therapeutic strategies for PAH.https://doi.org/10.1038/s41598-025-88887-4Pulmonary arterial hypertensionSerum uric acidUrate-lowering drugMendelian randomization |
| spellingShingle | Xiaoling Yao Xin Cai Shaoqin Zhang Yuzheng Yang Xiangyan Yang Wukai Ma Zong Jiang Mendelian randomization study of serum uric acid levels and urate-lowering drugs on pulmonary arterial hypertension outcomes Scientific Reports Pulmonary arterial hypertension Serum uric acid Urate-lowering drug Mendelian randomization |
| title | Mendelian randomization study of serum uric acid levels and urate-lowering drugs on pulmonary arterial hypertension outcomes |
| title_full | Mendelian randomization study of serum uric acid levels and urate-lowering drugs on pulmonary arterial hypertension outcomes |
| title_fullStr | Mendelian randomization study of serum uric acid levels and urate-lowering drugs on pulmonary arterial hypertension outcomes |
| title_full_unstemmed | Mendelian randomization study of serum uric acid levels and urate-lowering drugs on pulmonary arterial hypertension outcomes |
| title_short | Mendelian randomization study of serum uric acid levels and urate-lowering drugs on pulmonary arterial hypertension outcomes |
| title_sort | mendelian randomization study of serum uric acid levels and urate lowering drugs on pulmonary arterial hypertension outcomes |
| topic | Pulmonary arterial hypertension Serum uric acid Urate-lowering drug Mendelian randomization |
| url | https://doi.org/10.1038/s41598-025-88887-4 |
| work_keys_str_mv | AT xiaolingyao mendelianrandomizationstudyofserumuricacidlevelsandurateloweringdrugsonpulmonaryarterialhypertensionoutcomes AT xincai mendelianrandomizationstudyofserumuricacidlevelsandurateloweringdrugsonpulmonaryarterialhypertensionoutcomes AT shaoqinzhang mendelianrandomizationstudyofserumuricacidlevelsandurateloweringdrugsonpulmonaryarterialhypertensionoutcomes AT yuzhengyang mendelianrandomizationstudyofserumuricacidlevelsandurateloweringdrugsonpulmonaryarterialhypertensionoutcomes AT xiangyanyang mendelianrandomizationstudyofserumuricacidlevelsandurateloweringdrugsonpulmonaryarterialhypertensionoutcomes AT wukaima mendelianrandomizationstudyofserumuricacidlevelsandurateloweringdrugsonpulmonaryarterialhypertensionoutcomes AT zongjiang mendelianrandomizationstudyofserumuricacidlevelsandurateloweringdrugsonpulmonaryarterialhypertensionoutcomes |